The National Pharmaceutical Pricing Authority (NPPA) has established price limits for 53 medications, including those prescribed for anxiety and type 2 diabetes. Under the Ministry of Chemical and Fertilizers, the NPPA has released two lists containing drugs with price ceilings. The first list consists of 51 medications, while the second contains two.
The retail price for vildagliptin and metformin hydrochloride, used to manage blood sugar levels in individuals with type 2 diabetes, has been fixed at Rs 13.68 per tablet. Another medication for the same purpose, a combination of sitagliptin, pioglitazone, and metformin hydrochloride, has been priced at Rs 17.69.
Likewise, the cost of dapagliflozin+metformin+vildagliptin, used in the treatment of type 2 diabetes, has been set at Rs 19.11 per tablet.
For the management of depression and anxiety, the prices for paroxetine (controlled release) and clonazepam capsules have been set at Rs 15.81.
Additionally, the price of etoricoxib and paracetamol tablets, utilized for pain relief and fever management, has been determined as Rs 8.99.
In the second list, the NPPA has announced the prices of Dabigatran (110) and Dabigatran (150) as Rs 31.81 and Rs 35.59, respectively. These medications are used for the prevention and treatment of blood clots and strokes.
According to a report by Mint, the NPPA has instructed all drug manufacturers to adjust their prices in compliance with the established ceiling. Failure to adhere to the order may result in the requirement to refund the excess charges to the government.
The NPPA’s action follows closely after a report by the Indian Council of Medical Research (ICMR) revealed a 44 per cent increase in the number of diabetes patients in India over the past four years. The country currently has over 100 million individuals diagnosed with diabetes.